Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 7.51TCr 6.52TCr 6.06TCr 5.59TCr 11TCr 7,17100Cr 11TCr 72TCr 28TCr 3,56200Cr 28TCr 28TCr 11,97800Cr P/E 2026 *
16.7x
P/E 2027 * 14.6x
Enterprise Value 6.89TCr 5.98TCr 5.56TCr 5.13TCr 9.65TCr 6,57800Cr 9.83TCr 66TCr 26TCr 3,26700Cr 26TCr 25TCr 10,98700Cr EV / Sales 2026 *
4.1x
EV / Sales 2027 * 3.58x
Free-Float
72.32%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
1 day+6.17%
1 week+13.26%
Current month+18.41%
1 month+18.41%
3 months+4.42%
6 months-0.42%
Current year-4.34%
1 week 659.53
Extreme 659.53
740
1 month 625.7
Extreme 625.7
740
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-200 0.0002%
19/02/26 Fiscal year

Director

4,914 0.0048%
09/02/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+6.17%+13.26%+33.13%-1.04% 7.51TCr
+3.59%-8.70%+17.93%+178.94% 4.76TCr
+3.25%+52.70%+52.70%+52.70% 4.95TCr
-3.81%+6.32%-54.61%-54.17% 4.29TCr
-0.62%+3.64%+64.19%-21.60% 3.07TCr
-3.23%+5.40%+58.59%+94.94% 2.49TCr
+6.29%+1.58%+80.16%-51.19% 2.3TCr
-1.53%-3.61%-11.53%+150.58% 1.96TCr
+1.52%+4.63%+77.52%+132.33% 1.72TCr
-1.68%-0.95%+80.05%+138.64% 1.61TCr
Average +0.98%+2.90%+39.81%+62.01% 3.47TCr
Weighted average by Cap. +1.85%+3.86%+32.52%+48.18%

Financials

2026 *2027 *
Net sales 1.68TCr 1.46TCr 1.35TCr 1.25TCr 2.35TCr 1,60300Cr 2.4TCr 16TCr 6.28TCr 80TCr 6.31TCr 6.17TCr 2,67800Cr 1.8TCr 1.57TCr 1.46TCr 1.34TCr 2.53TCr 1,72300Cr 2.57TCr 17TCr 6.75TCr 86TCr 6.78TCr 6.63TCr 2,87800Cr
Net income 464.91Cr 403.82Cr 374.99Cr 345.84Cr 651.44Cr 44TCr 663.24Cr 4.44TCr 1.74TCr 22TCr 1.75TCr 1.71TCr 74TCr 523.48Cr 454.69Cr 422.24Cr 389.41Cr 733.51Cr 50TCr 746.79Cr 5TCr 1.96TCr 25TCr 1.97TCr 1.92TCr 83TCr
Net Debt -621.57Cr -539.9Cr -501.36Cr -462.38Cr -870.96Cr -59TCr -886.74Cr -5.94TCr -2.32TCr -29TCr -2.33TCr -2.28TCr -99TCr -1.06TCr -916.7Cr -851.27Cr -785.07Cr -1.48TCr -1,00800Cr -1.51TCr -10TCr -3.95TCr -50TCr -3.96TCr -3.88TCr -1,68300Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
30/26/30 $738.34 +6.17% 14,60,963
29/26/29 $695.42 +0.03% 10,22,421
28/26/28 $695.18 +4.20% 9,00,408
27/26/27 $667.17 +1.70% 6,50,984
24/26/24 $656.01 +0.63% 7,08,392
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
738.34USD
Average target price
825.28USD
Spread / Average Target
+11.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock